Cubist’s Time To Shine: Antibiotic Specialist Acquires Optimer, Trius
Executive Summary
Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.
You may also be interested in...
Under Pressure: Can Merck Show Cubist Is Worth $9.5 Billion Without Cubicin?
Hours after Merck revealed a merger agreement with Cubist, a court ruled that generic versions of Cubist’s big seller Cubicin can launch in 2016, two years earlier than expected, putting the pressure on Merck to justify the pricey acquisition.
Merck Pays Big To Expand Into Acute Care With Cubist Acquisition (Updated)
Merck agreed to pay $9.5 billion to acquire Cubist, gaining a portfolio of antibiotics for hard-to-treat infections as part of a broader strategy to expand in the acute care setting.
Cubist Leadership Transitions To Perez With ‘Strong Hand To Play’
President and Chief Operating Officer Robert Perez will succeed Michael Bonney as CEO effective Jan. 1, taking over the top leadership spot at a time when the specialty pharma is in the midst of a transformation into a multi-asset company.